A. Marcelin

发表

Comparison of two genotypic algorithms to determine HIV‐1 tropism *

V. Calvez, G. Carcelain, C. Katlama, 2008, HIV medicine.

Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.

V. Calvez, C. Charpentier, B. Masquelier, 2013, The Journal of antimicrobial chemotherapy.

Phylodynamics of SARS-CoV-2 transmissions in France, Europe and the world during 2020

V. Calvez, C. Charpentier, D. Descamps, 2022, medRxiv.

Routine screening for HIV, hepatitis B virus and hepatitis C virus in individuals undergoing oral and maxillofacial surgery

C. Katlama, P. Coriat, D. Costagliola, 2019, HIV medicine.

Upgraded Cobas Ampliprep-Cobas TaqMan Version 2.0 HIV-1 RNA Quantification Assay versus First Version: Correction of Underestimations

V. Calvez, R. Tubiana, C. Katlama, 2011, Journal of Clinical Microbiology.

Underestimations versus First Version : Correction of AssayVersion 2 . 0 HIV-1 RNA Quantification Upgraded Cobas Ampliprep-Cobas TaqMan

R. Tubiana, S. Fourati, C. Soulié, 2011 .

National survey of the prevalence and conditions of selection of HIV‐1 reverse transcriptase K70E mutation

V. Calvez, C. Delaugerre, S. Yerly, 2008, Journal of medical virology.

Disparities in HIV‐1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations

V. Calvez, C. Charpentier, C. Katlama, 2017, HIV medicine.

Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled European cohort data

J. Lundgren, V. Calvez, F. Ceccherini‐Silberstein, 2015, HIV medicine.

Pharmacokinetics, protein‐binding‐adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment‐naïve HIV‐infected patients *

V. Calvez, C. Katlama, G. Peytavin, 2010, HIV medicine.

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy *

V. Calvez, C. Delaugerre, C. Katlama, 2004, HIV medicine.

Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first‐line combination antiretroviral therapy

G. Carcelain, C. Katlama, B. Autran, 2015, HIV Medicine.

Cumulative incidence of SARS-CoV-2 infection and associated risk factors among frontline health care workers in Paris, France: the SEROCOV prospective cohort study

F. Tubach, D. Boutolleau, A. Combes, 2021, medRxiv.

Lack of evidence of an association between HHV-8 and multiple myeloma

V. Calvez, P. Ravaud, N. Dupin, 1998, Leukemia.

High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers

J. Spano, J. Gligorov, R. Palich, 2021, Annals of Oncology.

Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.

V. Calvez, R. Tubiana, C. Katlama, 2020, The Journal of antimicrobial chemotherapy.

Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.

V. Calvez, C. Katlama, F. Raffi, 2016, The Journal of antimicrobial chemotherapy.

Impact of Discrepancies between the Abbott RealTime and Cobas TaqMan Assays for Quantification of Human Immunodeficiency Virus Type 1 Group M Non-B Subtypes

V. Calvez, R. Tubiana, C. Katlama, 2009, Journal of Clinical Microbiology.

Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication

V. Calvez, A. Samri, C. Katlama, 2005, AIDS.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Stability of HIV RNA in plasma specimens stored at different temperatures

V. Calvez, C. Katlama, G. Brucker, 2008, HIV medicine.

Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.

V. Calvez, C. Charpentier, C. Katlama, 2012, The Journal of antimicrobial chemotherapy.

CORRESPONDENCE Lack of evidence of an association between HHV-8 and multiple myeloma

V. Calvez, P. Ravaud, P. Koeffler, 1998 .

Identification of new genotypic cut‐off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial

V. Calvez, A. Hill, A. Marcelin, 2009, HIV medicine.

Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen

V. Calvez, C. Charpentier, P. André, 2018, The Journal of antimicrobial chemotherapy.

Switch From Etravirine Twice Daily to Once Daily in Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Resistant HIV-Infected Patients With Suppressed Viremia: The Monetra Study

V. Calvez, C. Katlama, G. Peytavin, 2012, HIV clinical trials.

Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study

C. Katlama, D. Costagliola, J. Capeau, 2022, Journal of acquired immune deficiency syndromes.

Antiretroviral resistance at virologic failure in the NEAT 001 / ANRS 143 trial : Raltegravir + 1 Darunavir / ritonavir or Tenofovir / Emtricitabine + Darunavir / ritonavir as first line 2 antiretroviral therapy 3

H. Jessen, A. Blaxhult, V. Calvez, 2016 .